-
-
-
-
-
-
-
NeuroPace reports Q4 revenue of $26.6 million, up 24% year-over-year
-
-
-
-
-
-
-
NeuroPace (NPCE) Tops Q3 EPS by 9c
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)
-
-
-
-
-
-
-
H.C. Wainwright Starts NeuroPace Inc (NPCE) at Buy
-
-
-
-
-
-
-
NeuroPace Inc (NPCE) PT Lowered to $17 at Cantor Fitzgerald
-
-
-
-
-
-
-
NeuroPace Inc (NPCE) PT Raised to $20 at Cantor Fitzgerald
-
-
-
-
-
-
-
NeuroPace (NPCE) Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy
-
416,814 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

